One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Longer acne antibiotic duration increases recurrence and resistance without added benefit. Learn more about optimal treatment ...

Incyte INCY reported 54-week data from its late-stage STOP-HS program demonstrating substantial and sustained efficacy of povorcitinib in patients with moderate-to-severe hidradenitis suppurativa (HS) ...

The dreaded Indian summer season is almost here. Summers in India are not just about high temperatures, heat strokes, and ...

Understand how step therapy affects psoriasis treatment. Learn about the ‘fail first’ process, the impact of treatment delays ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) ...

People sharing pictures and accounts on socials of red, inflamed skin have triggered the first UK research into TSW.

Skin dysmorphia: Has your pursuit of beautiful skin become a mental health issue? - IN FOCUS : A mental health condition characterised by a fixation on slight, or entirely imaginary flaws on the skin, ...

Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...

March 28 (Reuters) - Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials. The company tested the drug, povorcitinib, in patients ...

Lilly's Ebglyss delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis: Indianapolis Monday, March 30, 2026, 12:00 Hrs [IST] ...

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...